Pamelor

Neuralgia, Postherpetic, Irritable Bowel Syndrome, Depression + 3 more

Treatment

1 FDA approval

20 Active Studies for Pamelor

What is Pamelor

Nortriptyline

The Generic name of this drug

Treatment Summary

Nortriptyline hydrochloride is an antidepressant medication used to treat major depression. It is also sometimes prescribed for chronic pain and other conditions, even though it is not approved for these uses. It is a type of tricyclic antidepressant that is derived from amitriptyline.

Pamelor

is the brand name

image of different drug pills on a surface

Pamelor Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Pamelor

Nortriptyline

1977

190

Approved as Treatment by the FDA

Nortriptyline, also known as Pamelor, is approved by the FDA for 1 uses including Depression .

Depression

Effectiveness

How Pamelor Affects Patients

Nortriptyline works as an antidepressant by blocking the removal of serotonin and norepinephrine from cells in the brain. It also blocks certain receptors in the body which can lead to muscle relaxation.

How Pamelor works in the body

Nortriptyline is believed to either stop nerves from reabsorbing serotonin or act on beta-adrenergic receptors. It is more effective at preventing the reabsorption of noradrenaline, which can explain why it's helpful for improving symptoms. Unlike other tricyclic antidepressants, nortriptyline does not impact monoamine oxidase or dopamine reuptake. It also has an affinity for mACh receptors, histamine receptors, and 5-HT receptors.

When to interrupt dosage

The measure of Pamelor is conditioned by the diagnosed affliction, including Irritable Bowel Syndrome (IBS), Depression and Chronic Pain. The measure of dosage evolves, as per the technique of administration (e.g. Oral or Capsule) delineated in the table beneath.

Condition

Dosage

Administration

Facial Pain

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 10.0 mg/mL, 2.0 mg/mL

, Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet - Oral, Tablet

Irritable Bowel Syndrome

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 10.0 mg/mL, 2.0 mg/mL

, Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet - Oral, Tablet

Depression

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 10.0 mg/mL, 2.0 mg/mL

, Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet - Oral, Tablet

Pain

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 10.0 mg/mL, 2.0 mg/mL

, Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet - Oral, Tablet

Neuralgia, Postherpetic

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 10.0 mg/mL, 2.0 mg/mL

, Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet - Oral, Tablet

Chronic Pain

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 10.0 mg/mL, 2.0 mg/mL

, Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet - Oral, Tablet

Warnings

Pamelor Contraindications

Condition

Risk Level

Notes

Dibenzazepines

Do Not Combine

Myocardial Infarction

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Nortriptyline may interact with Pulse Frequency

There are 20 known major drug interactions with Pamelor.

Common Pamelor Drug Interactions

Drug Name

Risk Level

Description

Acepromazine

Major

Nortriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Nortriptyline is combined with Aclidinium.

Alfuzosin

Major

Nortriptyline may increase the hypotensive activities of Alfuzosin.

Amoxapine

Major

Nortriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amoxapine.

Aripiprazole

Major

Nortriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.

Pamelor Toxicity & Overdose Risk

The lowest toxic dose of nortriptyline in rats is 405 mg/kg. Overdosing on nortriptyline can lead to abnormal heart rhythms, dangerously low blood pressure, shock, heart failure, fluid in the lungs, seizures, loss of consciousness, and central nervous system depression. Changes in the electrocardiogram may also be seen with nortriptyline toxicity.

image of a doctor in a lab doing drug, clinical research

Pamelor Novel Uses: Which Conditions Have a Clinical Trial Featuring Pamelor?

222 active studies are presently being conducted to evaluate the potential of Pamelor in providing relief from Pain, Orofacial, Depression and Irritable Bowel Syndrome (IBS).

Condition

Clinical Trials

Trial Phases

Neuralgia, Postherpetic

0 Actively Recruiting

Facial Pain

6 Actively Recruiting

Not Applicable, Early Phase 1, Phase 2

Irritable Bowel Syndrome

5 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1

Chronic Pain

0 Actively Recruiting

Depression

213 Actively Recruiting

Phase 3, Phase 2, Not Applicable, Phase 4, Phase 1, Early Phase 1

Pain

4 Actively Recruiting

Phase 2, Not Applicable, Early Phase 1

Pamelor Reviews: What are patients saying about Pamelor?

5

Patient Review

7/1/2013

Pamelor for Depression

While this drug did help with my depression and anxiety, the headaches it gave me were really severe. Aspirin helped a bit but then I started having stomach problems. constipation was also an unfortunate side effect.

4.7

Patient Review

12/18/2013

Pamelor for Depression

I started taking this medication on Friday 12/15/13 and have since felt electrical shocks around my ankle. These shocks last for 5-10 seconds before stopping. I've had this feeling 4 times today and wonder if the drug is causing these side effects?

4.7

Patient Review

7/21/2012

Pamelor for Depression

4

Patient Review

1/30/2014

Pamelor for Depression

This medication does exactly what it says it will do, with no negative side effects that I can tell. However, it is very expensive. Generics don't seem to work as well.

4

Patient Review

6/12/2014

Pamelor for Neuropathic Pain

Made me drowsy, but was otherwise effective.

3.7

Patient Review

6/27/2014

Pamelor for Neuropathic Pain

Pamelor has been a game-changer for me, managing my TBI symptoms and mood swings. The negatives are that it's caused some hair loss and weight gain, but those effects have been manageable.

3.7

Patient Review

1/23/2013

Pamelor for Depression

I'm not entirely sure what this is, but it seems to be working?

3.7

Patient Review

7/29/2014

Pamelor for Neuropathic Pain

Unfortunately, this medication caused me some pretty uncomfortable muscle shakes - especially in my hands.

3

Patient Review

11/19/2014

Pamelor for Neuropathic Pain

I had some trouble swallowing this medication.

2.7

Patient Review

2/17/2014

Pamelor for Depression

I've been taking a small dose of this for over two years now. It helps to reduce my anxiety and also makes it easier for me to fall asleep at night.

1

Patient Review

5/21/2015

Pamelor for Depression

Unfortunately, this medication made me so nauseated that I could only take it for a short time. Additionally, it left me feeling very anxious and "weird."

1

Patient Review

12/24/2012

Pamelor for Neuropathic Pain

I didn't sleep at all while taking this drug and my heart rate was constantly high.

1

Patient Review

9/25/2012

Pamelor for Neuropathic Pain

The dry mouth was the worst part, but other than that this drug was helpful.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about pamelor

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the drug Pamelor used for?

"This medication is used to treat depression. It may help improve mood, relieve anxiety, and increase energy levels."

Answered by AI

Is Pamelor a benzo?

"Pamelor and Xanax are two very different drugs that have some similarities in terms of side effects. Pamelor is a tricyclic antidepressant while Xanax is a benzodiazepine. Some of the side effects that these two drugs have in common include blurred vision, dry mouth, constipation, weight changes, dizziness, weakness, poor balance or coordination, nausea, and decreased sex drive."

Answered by AI

What type of drug is Pamelor?

"In chemistry, organic compounds are any chemical compounds that contain carbon-hydrogen or carbon-carbon bonds. Due to carbon's ability to catenate, there are millions of organic compounds known."

Answered by AI

What are the most common side effects of nortriptyline?

"The potential side effects of this medication include nausea, drowsiness, weakness or tiredness, excitement or anxiety, nightmares, dry mouth, changes in appetite or weight, and constipation."

Answered by AI

Clinical Trials for Pamelor

Have you considered Pamelor clinical trials?

We made a collection of clinical trials featuring Pamelor, we think they might fit your search criteria.
Go to Trials
Image of University of Rochester Medical Center in Rochester, United States.

Deaf CBT-TS for Suicide Risk

18+
All Sexes
Rochester, NY

The goal of this clinical trial is to learn if a short, Zoom-based intervention, Cognitive Behavioral Therapy for Treatment-Seeking for Deaf Individuals (Deaf CBT-TS) can change beliefs about mental health treatment and increase treatment-seeking behaviors in Deaf adults with untreated mental health or alcohol use problems. It will also see if Deaf CBT-TS may reduce suicide risk and explore factors that may increase the effectiveness of Deaf CBT-TS. The main questions it aims to answer are: * Does Deaf CBT-TS increase positive beliefs about treatment and increase treatment-seeking behaviors? * Does Deaf CBT-TS increase hope and reduce mental health symptoms, suicide ideation, and alcohol use? * Is Deaf CBT-TS more effective for individuals with less cultural stress compared to those with high levels of cultural stress? * Is Deaf CBT-TS more effective for Deaf individuals in residential areas with more Deaf resources than those with less Deaf resources? Researchers will compare individuals who complete Deaf CBT-TS to those on a waitlist to see if Deaf CBT-TS works to increase positive beliefs about treatment and treatment-seeking behaviors. Participants will: * Complete a baseline assessment including demographic information, measures of hope, general mental health and functioning, alcohol use, suicide ideation, cultural stress, and beliefs about treatment. * Receive Deaf CBT-TS (2 sessions) or be placed on a waitlist with the option of receiving Deaf CBT-Ts after 4 months * Complete two follow-up assessments in 2 and 4 months.

Waitlist Available
Has No Placebo

University of Rochester Medical Center

Image of Mayo Clinic in Rochester in Rochester, United States.

Tuina Treatment for Myofascial Pain

18+
All Sexes
Rochester, MN

The purpose of this research is to develop and test new Magnetic Resonance Imaging (MRI) methods that look at how muscles and tissues under the skin (myofascial tissues) move and respond to pressure. The investigators want to see how these tissues differ between healthy people and people with pain or injury, and how they change after hands-on treatment (Tuina therapy). The results will also be compared to a group that receives standard care without Tuina therapy. The main questions this study aims to answer are: 1. Can MR elastography (MRE) show changes in how the fascia and the layers between muscles move and stretch before and after manual therapy? 2. Do changes seen on MRE scans match changes in pain, function, and other symptoms reported by participants? 3. Can MRE measurements before treatment help predict which participants are most likely to improve with manual therapy? In this randomized controlled trial, participants with myofascial pain will be randomly assigned (randomized) to either the Tuina group or the Usual Care group following a home-based care program without manual therapy. All treatments are noninvasive, hands-on techniques commonly used in clinical practice to reduce tissue tightness and improve movement. Participants will be asked to undergo three MRI scans and to complete questionnaires and other standard clinical assessments about their pain, physical function, and quality of life.

Waitlist Available
Has No Placebo

Mayo Clinic in Rochester

Ziying Yin, Ph.D.

Image of Sunwise Clinical Research /ID# 277555 in Walnut Creek, United States.

Icalcaprant for Depression

18 - 65
All Sexes
Walnut Creek, CA

Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, tiredness, changes in eating habits, and aches and pains. This study will assess the changes in disease activity and adverse events of oral Icalcaprant in adult participants with major depressive disorder who are currently experiencing a major depressive episode (MDE). Icalcaprant is an investigational drug being developed for the treatment of depressive episodes in adult participants with major depressive disorder. Participants are placed in 1 of 3 groups, called treatment arms. There is a 1 in 3 chance that a participant will be assigned to placebo treatment. Around 195 adult participant with major depressive disorder will be enrolled in approximately 35 sites in North America. Participants will receive oral capsules of Icalcaprant or matching placebo once daily for 6 weeks, with a 30-day safety follow-up. There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Phase 2
Recruiting

Sunwise Clinical Research /ID# 277555 (+12 Sites)

ABBVIE INC.

AbbVie

Have you considered Pamelor clinical trials?

We made a collection of clinical trials featuring Pamelor, we think they might fit your search criteria.
Go to Trials
Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA

While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.

Phase < 1
Waitlist Available

Stanford Digestive Health Clinic (+1 Sites)

Sean P Spencer, MD, PhD

Image of Loyola University Medical Center in Maywood, United States.

Core Strengthening for TMJ Disorder

18 - 80
All Sexes
Maywood, IL

Temporomandibular disorders (TMD) are commonly managed with non-invasive interventions such as manual therapy, therapeutic exercise, relaxation techniques, and patient education. Core strengthening (also known as abdominal strengthening) is a fundamental element of physical therapy that engages deep and superficial trunk musculature to enhance postural control and functional performance. Protocols such as the Shirley Sahrmann progression have demonstrated increased activation of key core stabilizing muscles. Emerging evidence suggests a potential relationship between core stability training and reductions in TMD-related pain, though improvements in functional outcomes remain inconclusive. Biomechanical links between the pelvic floor, spine, and temporomandibular joint further support the rationale for core-focused interventions. Nevertheless, few studies have isolated the effects of core strengthening on TMD symptomatology. This study seeks to determine whether the integration of core stability exercises into TMD management can reduce pain, improve function, and enhance quality of life.

Waitlist Available
Has No Placebo

Loyola University Medical Center

Have you considered Pamelor clinical trials?

We made a collection of clinical trials featuring Pamelor, we think they might fit your search criteria.
Go to Trials